Matthew Gallitto

Mount Sinai Health System, Icahn School of Medicine at Mount Sinai

Papers

Total Citations

H-Index

About

Matthew Gallitto is a leading clinical researcher in head and neck oncology, with a focused expertise in human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC). His major contributions center on refining surgical and radiotherapeutic strategies to minimize overtreatment while improving oncologic outcomes. Gallitto’s seminal 2021 work, “Redefining risk of contralateral cervical nodal disease in early stage oropharyngeal cancer in the human papillomavirus era” (14 citations), challenged conventional treatment paradigms by identifying pathologic risk factors for contralateral nodal spread, enabling more selective neck management. His 2019 study on trimodality therapy in the transoral robotic surgery (TORS) era (13 citations) critically evaluated which patients truly benefit from aggressive combined-modality treatment, highlighting toxicity trade-offs and outcomes. These studies, together with his earlier pathologic analysis of bilateral neck dissection specimens (2 citations), have helped redefine risk stratification for HPV-positive OPSCC patients. Gallitto’s work is highly influential in guiding de-escalation protocols and personalized treatment decisions, directly impacting clinical guidelines and reducing unnecessary morbidity. His research is essential reading for surgeons, radiation oncologists, and trainees navigating the evolving landscape of HPV-related oropharyngeal cancer management.